Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows

The progressive constituent successful Eli Lilly's (LLY) flagship weight-loss supplier has a caller imaginable indication: bosom nonaccomplishment treatment.

Tirzepatide, sold arsenic Mounjaro to dainty Type 2 glucosuria and Zepbound for obesity, reduced nan consequence of bosom nonaccomplishment outcomes by 38% versus placebo successful a Phase 3 objective trial, nan institution said Thursday. 

The SUMMIT proceedings evaluated nan information and efficacy of nan supplier successful adults pinch bosom nonaccomplishment pinch preserved ejection fraction (HFpEF) and obesity. In summation to improved bosom nonaccomplishment outcomes, participants besides saw an mean of 15.7% simplification successful assemblage weight, compared pinch 2.2% for placebo. 

Eli Lilly said it plans to taxable nan results of nan proceedings to nan Food and Drug Administration (FDA) and different regulators later this year. 

Shares of nan drugmaker roseate astir 3% to $826.98 arsenic of noon ET Thursday. They are up much than 40% this year.